MMEA
KRYS icon

Main Management ETF Advisors’s Krystal Biotech KRYS Stock Holding History

Main Management ETF Advisors’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,179
Closed -$2.51M – 154
2025
Q4 		$2.51M Buy
10,179
+104
+1% +$21.9K 0.09% 38
2025
Q3 		$1.78M Buy
10,075
+4,944
+96% +$740K 0.07% 61
2025
Q2 		$705K Buy
5,131
+84
+2% +$12.3K 0.03% 118
2025
Q1 		$910K Buy
5,047
+1,487
+42% +$250K 0.04% 73
2024
Q4 		$558K Sell
3,560
-320
-8% -$56.8K 0.03% 131
2024
Q3 		$706K Buy
+3,880
New +$748K 0.03% 130

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Main Management ETF Advisors's KRYS Position: Q1 2026 in Review

Main Management ETF Advisors sold out of Krystal Biotech (KRYS) in Q1 2026, closing a stake of 10,179 shares — an estimated $2.51M sold.

Main Management ETF Advisors first reported a position in KRYS in Q3 2024 and held it in 6 quarters. The position peaked at $2.51M in Q4 2025. 368 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • Main Management ETF Advisors reported no remaining Krystal Biotech position as of Q1 2026 after selling out during the quarter.
  • Main Management ETF Advisors sold 10,179 Krystal Biotech shares in Q1 2026, an estimated $2.51M.
  • Main Management ETF Advisors first reported a position in Krystal Biotech in Q3 2024 and held it in 6 quarters.
  • Main Management ETF Advisors's Krystal Biotech position peaked at $2.51M in Q4 2025.
  • 368 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Main Management ETF Advisors's 13F filing for Q1 2026, filed 15 May 2026.